LEE'S PHARM.
李 氏 大 藥 廠

Lee's Pharmaceutical Holdings Limited
李氏大藥廠控股有限公司*

(incorporated in the Cayman Islands with limited liability)
(Stock Code: 950)

VOLUNTARY ANNOUNCEMENT
SHARE REPURCHASE PROGRAM
UNDER THE REPURCHASE MANDATE

This announcement is made by the board (the "**Board**") of directors (the "**Directors**") of Lee's Pharmaceutical Holdings Limited (the "**Company**") on a voluntary basis.

The Board of the Company is pleased to announce that the Company has decided to implement a share repurchase program (the "**Share Repurchase Program**") through the exercise of the general mandate to repurchase shares of the Company (the "**Shares**") granted by the shareholders of the Company to the Board at the annual general meeting of the Company held on 21 May 2026 (the "**Repurchase Mandate**"). The Company will repurchase its Shares from the open market.

The Share Repurchase Program, subject to the Repurchase Mandate, will authorise the Company to repurchase Shares for an aggregate consideration of no more than HK$50 million during the period commencing from 16 June 2026 to the conclusion of the next annual general meeting of the Company, or the expiration of the period within which the next annual general meeting of the Company is required by the memorandum and articles of association of the Company or any applicable laws to be held, or the date upon which the authority under the Repurchase Mandate is revoked or varied by way of an ordinary resolution of the shareholders of the Company in general meeting, whichever is the earliest.

Pursuant to the Repurchase Mandate, the Company is allowed to repurchase its own Shares up to 10% of the total number of Shares in issue as of the date of passing of the relevant resolutions granting the Repurchase Mandate (i.e. 58,883,534 Shares).

* *For identification purpose only*

Under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"), the repurchase price of each Share shall not be more than 5% above the average closing market price for the Shares over the 5 trading days immediately preceding each repurchase.

The Company intends to finance the repurchase of Shares by its own resources while maintaining sufficient financial resources for the continued growth of its operations.

The Board believes that the current share price of the Company is below both its intrinsic value and the value perceived by investors, presenting a favourable opportunity to repurchase Shares. The Share Repurchase Program reflects the confidence of the Board in the current business development and future prospects of the Company. Furthermore, the Company believes that actively managing its capital structure through the Share Repurchase Program will optimise the capital structure of the Company, enhance earnings per share, and improve overall shareholder returns.

The Share Repurchase Program will be conducted pursuant to the Repurchase Mandate and in compliance with the memorandum and articles of association of the Company, the Listing Rules, the Codes on Takeovers and Mergers and Share Buy-backs (the "**Takeovers Code**") and all other applicable laws and regulations. Any Shares repurchased by the Company will be cancelled. Shareholders and potential investors should note that any repurchase of Shares by the Company under the Share Repurchase Program will be subject to market conditions and will be at the absolute discretion of the management of the Company. There is no assurance as to the timing, quantity or price of any share repurchases, or whether or not the Company will make any repurchases. The Directors have no intention to exercise the Repurchase Mandate to the extent that would give rise to an obligation to make a general offer to shareholders of the Company under Rules 26 and 32 of the Takeovers Code.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Lee's Pharmaceutical Holdings Limited
Lee Siu Fong
Chairman

Hong Kong, 16 June 2026

As at the date of this announcement, Ms. Lee Siu Fong (Chairman) and Ms. Leelalertsuphakun Wanee are executive directors of the Company, Dr. Li Xiaoyi, Mr. James Charles Gale and Mr. Huang Zuie-Chin are non-executive directors of the Company, and Dr. Chan Yau Ching, Bob, Ms. Cheang Yee Wah, Eva and Dr. Tsim Wah Keung, Karl are independent non-executive directors of the Company.